Skip to content

Lung squamous cell carcinoma — central-airway biology and presentation

TL;DR — LUSC is historically a central-airway cancer, but peripheral tumors are now common enough that location cannot define histology: one resection series contained 120 peripheral and 148 central tumors (Lin 2019, PMID 30456676). Its distinctive opportunity is a visible precursor field—metaplasia, dysplasia, carcinoma in situ (CIS), then invasion—but longitudinal evidence does not support an inevitable linear march; many lesions regress, while new cancers arise elsewhere in the injured airway (Ishizumi 2010, PMID 20112052). In 164 surveilled patients, 61 cancers developed and 59% arose at sites separate from the index lesion, demonstrating field risk rather than a single-lesion problem (van Boerdonk 2015, PMID 26275031). Central growth creates hazards not captured by diameter alone: obstruction, post-obstructive infection, atelectasis, and hemoptysis; malignant central-airway obstruction affected at least 25% of the lumen in 17% of one lung-cancer cohort and was most strongly associated with squamous and small-cell histology (Ivanick 2024, PMID 38881337). CT can miss superficial central disease, so bronchoscopy remains important when symptoms, sputum atypia, or airway findings remain discordant with cross-sectional imaging (Zhou 2024, PMID 38443800).

Central is characteristic, not universal

“Central” generally denotes a tumor arising in or involving the trachea, main bronchi, lobar bronchi, or segmental bronchi; study definitions vary. “Peripheral” usually means a parenchymal lesion beyond these airways, but cutoffs based on inner/outer lung thirds are also used. This definitional variability prevents a single defensible central-LUSC percentage (Tomashefski 1990, PMID 2334253; Lin 2019, PMID 30456676).

Cohort Central/peripheral finding Associated features Source
268 resected LUSC, 1990–2013 148 central; 120 peripheral Peripheral tumors were smaller, earlier-stage, more often in women, and less node-positive Lin 2019, PMID 30456676
Historical pathologic comparison Central and peripheral LUSC showed clinicopathologic differences Survival differences were not a stable defining feature Tomashefski 1990, PMID 2334253
Peripheral LUSC series Peripheral tumors form a recognizable clinicopathologic subset Demonstrates that peripheral location does not imply adenocarcinoma Funai 2003, PMID 12826890; Sakurai 2004, PMID 15223433
Contemporary commentary Apparent anatomic shift toward peripheral squamous tumors May reflect cigarette design, imaging, or classification change Krimsky 2016, PMID 27987285

In the Lin cohort, peripheral location correlated with smaller tumors and less nodal metastasis, yet location itself was not independently associated with progression-free or overall survival. Lymphovascular invasion and nodal metastasis, not the central/peripheral label, carried prognostic information among peripheral tumors (Lin 2019, PMID 30456676).

The precursor sequence—and why the ladder is too simple

The classical morphologic model is:

Stage Morphology Biological interpretation What it does not establish
Basal-cell hyperplasia Expanded basal compartment Response to chronic epithelial injury Clonal neoplasia by itself
Squamous metaplasia Ciliated epithelium replaced by squamous epithelium Adaptive but exposure-linked change Inevitable progression
Mild/moderate dysplasia Increasing atypia and disordered maturation Elevated field and lesion risk Which individual lesion will persist
Severe dysplasia High-grade architectural/cytologic atypia High-risk precursor That invasion is imminent
Carcinoma in situ Full-thickness atypia without basement-membrane invasion Molecularly and clinically distinct high-grade lesion Metastatic potential before invasion
Invasive LUSC Basement membrane breached Access to lymphovascular routes That it arose contiguously from the observed lesion

The morphologic continuum is supported by cross-sectional pathology, but direct observation of each step in one lesion is uncommon. Reviews emphasize weak evidence for a universal stepwise progression and stronger evidence for field carcinogenesis, lesion regression, and multifocal emergence (Banerjee 2009, PMID 19279508; Ishizumi 2010, PMID 20112052).

In a 124-patient surveillance cohort with 240 preinvasive lesions and normal baseline CT, 20 patients developed CIS or cancer. Only three events represented observed local progression from severe dysplasia to CIS; seven were new endobronchial lesions and ten were new peripheral lesions. Cumulative CIS/cancer risk reached 7% at one year, 20% at three years, and 44% at five years (Alaa 2011, PMID 21040997).

Long-term surveillance of 164 subjects similarly detected 61 lung cancers in 55 people: 38 (62%) by autofluorescence bronchoscopy (AFB), 23 (38%) by CT, and 36 (59%) at sites separate from the initial lesion (van Boerdonk 2015, PMID 26275031). The unit of risk is therefore the person and airway field, not merely the biopsied plaque.

Molecular evolution of the airway field

Event or program Evidence Interpretation
3p allelic loss Accumulates across premalignant grades Early genomic instability within smoke-injured epithelium; Thiberville 1995, PMID 7585560
TP53/EGFR aberrant expression Detected in early bronchial neoplasia; coexpression can precede invasive cancer Early selection, not a clinically validated progression test; Rusch 1995, PMID 7882337
Progressive 3q amplification All high-grade but no low-grade lesions in a 19-biopsy study; 8/10 high-grade cases progressed SOX2 and PIK3CA were within the common amplicon; McCaughan 2010, PMID 20299530
Spatial clonal relatedness Discrete CIS lesions could share molecular ancestry over years Field cancerization can include migration/clonal dispersal; Pipinikas 2014, PMID 24550057
Persistent-lesion transcriptome 395 genes and 31 pathways differed between persistent/progressive and regressive sites Cell-cycle, inflammation, and adhesion programs may stratify risk; Merrick 2018, PMID 29997230
Four premalignant molecular subtypes Proliferative lesions showed cell-cycle activation and progressive lesions lost immune signaling/cells Supports immune interception hypotheses; Beane 2019, PMID 31015447
microRNA evolution Expression changes across human squamous carcinogenesis Candidate markers remain investigational; Mascaux 2009, PMID 19010987

The 3q study was small—19 biopsies from 15 patients—but its grade-linked copy-number pattern connects the precursor field to the SOX2/PIK3CA-amplified invasive genome (McCaughan 2010, PMID 20299530). The molecular-subtype work suggests that progression may involve both epithelial proliferation and local immune escape, a hypothesis not yet validated as a screening or treatment decision rule (Beane 2019, PMID 31015447).

Surveillance evidence

Strategy/evidence Population Result Inference
AFB + CT surveillance 124 people, 240 lesions 44% cumulative CIS/cancer risk at 5 years High-risk cohort; new severe dysplasia, COPD, and >52 pack-years predicted risk
AFB + CT surveillance 164 people, median 30 months 61 cancers; 59% separate-site High-grade lesions mark person-level field risk
Intensive vs standard AFB (SELEPREBB) 364 randomized patients with low-grade lesions OR 0.63 (95% CI 0.20–1.96) for invasive cancer/persistent CIS; no arm difference Six-monthly bronchoscopy did not improve outcomes
Baseline mild/moderate dysplasia in SELEPREBB 74 with dysplasia 5-year lung-cancer OR 5.9 (2.9–12.0) Histology may risk-stratify even when intensive surveillance fails
Smoking cessation in SELEPREBB Trial cohort, observational comparison Dysplasia clearance OR 0.12 (0.01–0.66); 5-year cancer OR 0.15 (0.003–0.99) Large but imprecise, non-randomized cessation association

AFB improves visualization of abnormal mucosa compared with white-light bronchoscopy, but false positives and selection of extremely high-risk cohorts limit general-population use (Kurie 1998, PMID 9665147; Loewen 2007, PMID 17101735). Sputum cytology preferentially detects central squamous disease but lacks sensitivity for population screening; atypia may instead identify a subgroup for airway evaluation (Lam 2009, PMID 19010567; Byers 2008, PMID 18199720).

Why CT may be insufficient centrally

CT excels at parenchymal nodules but may not distinguish subtle mucosal thickening from normal airway wall or reveal a flat CIS. In a retrospective bronchoscopy-room cohort of 10,851 primary lung cancers, 115 CT-occult central LUSCs and 15 squamous precursors were found—1.20% of all included lung cancers. Operable central LUSC had larger median diameter (3.65 vs 1.70 cm) and higher nodal metastasis (50.99% vs 13.06%) than peripheral adenocarcinoma, though the cross-histology comparison cannot isolate location (Zhou 2024, PMID 38443800).

This does not justify bronchoscopy as a general screening test. It supports targeted bronchoscopy for unexplained hemoptysis, focal obstruction/atelectasis, persistent sputum atypia, or high-risk airway lesions despite non-diagnostic CT (Kennedy 2005, PMID 16022912; Zhou 2024, PMID 38443800).

Clinical presentation by mechanism

Mechanism Presentation or finding Research significance
Endobronchial mucosal growth Cough, hemoptysis, abnormal sputum cytology Can precede a conspicuous CT mass; Latimer 2018, PMID 29313654; Zhou 2024, PMID 38443800
Progressive luminal narrowing Dyspnea, monophonic wheeze, stridor, lobar collapse Requires anatomic assessment and sometimes urgent therapeutic bronchoscopy; Ivanick 2024, PMID 38881337
Distal secretion retention Recurrent or non-resolving pneumonia, fever, atelectasis Post-obstructive pneumonia may be the presenting syndrome and can be difficult to eradicate without relieving obstruction; Rolston 2018, PMID 29392577
Tumor necrosis/cavitation Air-filled cavity, infection mimic, hemoptysis Cavitation is enriched in squamous histology and can mark adverse prognosis; Onn 2005, PMID 16183941
Bronchial-artery erosion Severe hemoptysis Most severe NSCLC bleeding arose from bronchial rather than pulmonary arteries; Razazi 2015, PMID 25359349
PTHrP secretion Hypercalcemia, dehydration, neurocognitive change LUSC was the commonest single cause in one PTHrP-hypercalcemia series; Donovan 2015, PMID 25719931

Central-airway obstruction

In a single-center imaging cohort, malignant central-airway obstruction of at least 25% luminal compromise was present in 17% at lung-cancer diagnosis; another 8.2% developed it within five years. Squamous and small-cell histologies had the strongest associations, and obstruction was associated with shorter survival (adjusted HR 1.702) (Ivanick 2024, PMID 38881337).

Obstruction is partly reversible morbidity. Among 52 advanced-NSCLC patients treated with therapeutic bronchoscopy plus systemic therapy, median survival was 8.4 months versus 8.2 months in 92 patients without obstruction receiving chemotherapy; the nonrandomized comparison suggests successful airway restoration can prevent obstruction from being an automatic therapeutic dead end (Chhajed 2006, PMID 17167000). Patient selection and immortal-time bias limit causal interpretation.

Bronchoscopic options include mechanical debulking, thermal ablation, cryotherapy, photodynamic therapy, dilation, and stenting; technique depends on whether obstruction is intraluminal, extrinsic, or mixed. Contemporary guidance treats therapeutic bronchoscopy as an adjunct to systemic therapy and/or radiation, not a substitute (Mahmood 2025, PMID 39029785; Chaddha 2024, PMID 38812262).

Hemoptysis and cavitation

In 125 consecutive NSCLC patients admitted with more than 100 mL hemoptysis, 65 (52%) had squamous histology and 26 (21%) had tumor cavitation or necrosis. Bleeding was bronchial-arterial in 82%; interventional radiology achieved cessation in 87%. In-hospital survival was 69% and one-year survival 30%; advanced stage, poor performance status, mechanical ventilation, progression, and cavitation predicted mortality (Razazi 2015, PMID 25359349).

Among 72 resected stage-I NSCLCs, cavitation occurred in 16 (22%), was more frequent in squamous than adenocarcinoma, and correlated with shorter disease-free and overall survival. The small retrospective cohort supports cavitation as a risk marker, not a stand-alone staging variable (Onn 2005, PMID 16183941).

Paraneoplastic hypercalcemia

PTHrP links squamous differentiation to a recognizable metabolic emergency. In 138 cases of PTHrP-mediated hypercalcemia, solid tumors caused 82.6%; squamous cancers were 28.2% of all cases, and lung LUSC was the single most common etiology (10.9%). Median survival for solid-tumor cases was 52 days (IQR 21–132), emphasizing that this series captured advanced systemic illness (Donovan 2015, PMID 25719931).

Hypercalcemia is not specific to LUSC, and calcium level did not discriminate cause in that cohort. Its value here is as a presentation/safety signal requiring etiologic evaluation, not as a diagnostic biomarker (Donovan 2015, PMID 25719931).

Open questions

  • Which molecular combination—3q/SOX2 amplification, cell-cycle activation, and immune depletion—best predicts that an individual dysplastic lesion will persist or invade (McCaughan 2010, PMID 20299530; Merrick 2018, PMID 29997230; Beane 2019, PMID 31015447)?
  • Can a noninvasive airway signature identify the high-risk field without repeated bronchoscopy, given that most cancers arise away from the index lesion (van Boerdonk 2015, PMID 26275031)?
  • Why did intensive six-monthly bronchoscopy fail to improve outcomes despite strong risk stratification by dysplasia, and would biomarker-guided rather than grade-guided surveillance succeed (Guisier 2022, PMID 35236723)?
  • What is the contemporary prevalence of CT-occult central LUSC in population screening rather than referral bronchoscopy cohorts (Zhou 2024, PMID 38443800)?
  • Can immune interception reverse progressive premalignant lesions without creating unacceptable toxicity in cancer-free high-risk individuals (Beane 2019, PMID 31015447)?

References

  1. Tomashefski JF Jr, Connors AF Jr, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med. 1990;114(5):468-74. PMID 2334253
  2. Funai K, Yokose T, Ishii G, Araki K, Yoshida J, Nishimura M, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003;27(7):978-84. PMID 12826890
  3. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg. 2004;78(1):222-7. PMID 15223433
  4. Lin MW, Huang YL, Yang CY, Kuo SW, Wu CT, Chang YL. The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma. Ann Surg Oncol. 2019;26(1):217-229. PMID 30456676
  5. Krimsky W, Muganlinskaya N, Sarkar S, Vulchi M, Patel P, Rao S, et al. The changing anatomic position of squamous cell carcinoma of the lung - a new conundrum. J Community Hosp Intern Med Perspect. 2016;6(6):33299. PMID 27987285
  6. Banerjee AK. Preinvasive lesions of the bronchus. J Thorac Oncol. 2009;4(4):545-51. PMID 19279508
  7. Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev. 2010;29(1):5-14. PMID 20112052
  8. Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res. 1995;55(22):5133-9. PMID 7585560
  9. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 1995;55(6):1365-72. PMID 7882337
  10. Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J. 2009;33(2):352-9. PMID 19010987
  11. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med. 2010;182(1):83-91. PMID 20299530
  12. Pipinikas CP, Kiropoulos TS, Teixeira VH, Brown JM, Varanou A, Falzon M, et al. Cell migration leads to spatially distinct but clonally related airway cancer precursors. Thorax. 2014;69(6):548-57. PMID 24550057
  13. Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, et al. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018;78(17):4971-4983. PMID 29997230
  14. Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, et al. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat Commun. 2019;10(1):1856. PMID 31015447
  15. Alaa M, Shibuya K, Fujiwara T, Wada H, Hoshino H, Yoshida S, et al. Risk of lung cancer in patients with preinvasive bronchial lesions followed by autofluorescence bronchoscopy and chest computed tomography. Lung Cancer. 2011;72(3):303-8. PMID 21040997
  16. van Boerdonk RA, Smesseim I, Heideman DA, Coupé VM, Tio D, Grünberg K, et al. Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. Am J Respir Crit Care Med. 2015;192(12):1483-9. PMID 26275031
  17. Guisier F, Deslee G, Birembaut P, Escarguel B, Chapel F, Bota S, et al. Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial. Eur Respir J. 2022;60(3). PMID 35236723
  18. Kurie JM, Lee JS, Morice RC, Walsh GL, Khuri FR, Broxson A, et al. Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst. 1998;90(13):991-5. PMID 9665147
  19. Loewen G, Natarajan N, Tan D, Nava E, Klippenstein D, Mahoney M, et al. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax. 2007;62(4):335-40. PMID 17101735
  20. Lam B, Lam SY, Wong MP, Ooi CG, Fong DY, Lam DC, et al. Sputum cytology examination followed by autofluorescence bronchoscopy: a practical way of identifying early stage lung cancer in central airway. Lung Cancer. 2009;64(3):289-94. PMID 19010567
  21. Byers T, Wolf HJ, Franklin WA, Braudrick S, Merrick DT, Shroyer KR, et al. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev. 2008;17(1):158-62. PMID 18199720
  22. Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, et al. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer. 2005;49(2):187-91. PMID 16022912
  23. Zhou J, Yu B, Guo P, Wang S. The insufficiency of CT examination in early detection of central lung squamous cell carcinoma and squamous epithelial precancerous lesions. BMC Cancer. 2024;24(1):299. PMID 38443800
  24. Latimer KM. Lung Cancer: Clinical Presentation and Diagnosis. FP Essent. 2018;464:23-26. PMID 29313654
  25. Ivanick NM, Kunadharaju R, Bhura S, Mengiste H, Saeed M, Saradna A, et al. Epidemiology and Survival of Malignant Central Airway Obstruction in Lung Cancer Identified on Cross-Sectional Imaging. J Bronchology Interv Pulmonol. 2024;31(3). PMID 38881337
  26. Chhajed PN, Baty F, Pless M, Somandin S, Tamm M, Brutsche MH. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. Chest. 2006;130(6):1803-7. PMID 17167000
  27. Rolston KVI, Nesher L. Post-Obstructive Pneumonia in Patients with Cancer: A Review. Infect Dis Ther. 2018;7(1):29-38. PMID 29392577
  28. Mahmood K, Frazer-Green L, Gonzalez AV, Shofer SL, Argento AC, Welsby I, et al. Management of Central Airway Obstruction: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025;167(1):283-295. PMID 39029785
  29. Chaddha U, Agrawal A, Kurman J, Ortiz-Comino R, Dutau H, Freitag L, et al. World Association for Bronchology and Interventional Pulmonology (WABIP) guidelines on airway stenting for malignant central airway obstruction. Respirology. 2024;29(7):563-573. PMID 38812262
  30. Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology. 2005;237(1):342-7. PMID 16183941
  31. Razazi K, Parrot A, Khalil A, Djibre M, Gounant V, Assouad J, et al. Severe haemoptysis in patients with nonsmall cell lung carcinoma. Eur Respir J. 2015;45(3):756-64. PMID 25359349
  32. Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab. 2015;100(5):2024-9. PMID 25719931